Biomarkers for prostate cancer

Danil V. Makarov, Stacy Loeb, Robert H. Getzenberg, Alan W. Partin

Research output: Contribution to journalReview articlepeer-review

149 Scopus citations


The development of biomarkers for prostate cancer screening, detection, and prognostication has revolutionized the management of this disease. Prostate-specific antigen (PSA) is a useful, though not specific, biomarker for detecting prostate cancer.We review the literature on prostate cancer biomarkers, including serum markers (PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2), tissue markers (AMACR, methylated GSTP1, and the TMPRSS2-ETS gene rearrangement), and a urine marker (DD3PCA3/UPM-3). Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer.

Original languageEnglish (US)
Pages (from-to)139-151
Number of pages13
JournalAnnual review of medicine
StatePublished - Jul 24 2009


  • Blood test
  • Prostate biopsy
  • Prostate-specific antigen (PSA)
  • Radical prostatectomy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Biomarkers for prostate cancer'. Together they form a unique fingerprint.

Cite this